Protagonist Therapeutics, Inc Stock Split Ratio
Protagonist Therapeutics, Inc (PTGX) reported Stock Split Ratio of 6.90% for the 1-month period ending 2016-07-31, per its 10-K filed 2018-03-07.
Discontinued › Notes › Equity › Stockholders' Equity Note
us-gaap:StockholdersEquityNoteStockSplitConversionRatio1 · last filed 2018-03-07
- 2016-07-31: Stockholders' Equity Note, Stock Split, Conversion Ratio 1 month 6.90%; Stockholders' Equity Note, Stock Split, Conversion Ratio 1 month as first filed 6.90%.
| Period end | Stockholders' Equity Note, Stock Split, Conversion Ratio 1 month | Stockholders' Equity Note, Stock Split, Conversion Ratio 1 month as first filed |
|---|---|---|
| 2016-07-31 | 6.90% 10-K · filed 2018-03-07 | 6.90% 10-Q · filed 2016-11-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| TG THERAPEUTICS, INC. (TGTX) | United States | $8.805B | 19.05 |
| CYTOKINETICS INC (CYTK) | United States | $9.130B | -11.86 |
| ARROWHEAD PHARMACEUTICALS, INC. (ARWR) | United States | $9.331B | -42.28 |
| Praxis Precision Medicines, Inc. (PRAX) | United States | $7.884B | -27.60 |
| Structure Therapeutics Inc. (GPCR) | United States | $7.710B | -53.41 |
| Spyre Therapeutics, Inc. (SYRE) | United States | $7.685B | -43.69 |
| Axsome Therapeutics, Inc. (AXSM) | United States | $10.274B | -66.82 |
| IONIS PHARMACEUTICALS INC (IONS) | United States | $7.277B | -23.25 |
| Alkermes plc. (ALKS) | $6.844B | 132.74 | |
| RHYTHM PHARMACEUTICALS, INC. (RYTM) | United States | $6.771B | -37.20 |